Cargando…

Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms

Detection of host cell protein (HCP) impurities is critical to ensuring that recombinant drug products, including monoclonal antibodies (mAbs), are safe. Mechanistic characterization as to how HCPs persist in drug products is important to refining downstream processing. It has been hypothesized that...

Descripción completa

Detalles Bibliográficos
Autores principales: Hecht, Elizabeth Sara, Mehta, Shrenik, Wecksler, Aaron T., Aguilar, Ben, Swanson, Nathaniel, Phung, Wilson, Dubey Kelsoe, Ananya, Benner, W. Henry, Tesar, Devin, Kelley, Robert F., Sandoval, Wendy, Sreedhara, Alavattam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621051/
https://www.ncbi.nlm.nih.gov/pubmed/36284469
http://dx.doi.org/10.1080/19420862.2022.2135183
_version_ 1784821452531302400
author Hecht, Elizabeth Sara
Mehta, Shrenik
Wecksler, Aaron T.
Aguilar, Ben
Swanson, Nathaniel
Phung, Wilson
Dubey Kelsoe, Ananya
Benner, W. Henry
Tesar, Devin
Kelley, Robert F.
Sandoval, Wendy
Sreedhara, Alavattam
author_facet Hecht, Elizabeth Sara
Mehta, Shrenik
Wecksler, Aaron T.
Aguilar, Ben
Swanson, Nathaniel
Phung, Wilson
Dubey Kelsoe, Ananya
Benner, W. Henry
Tesar, Devin
Kelley, Robert F.
Sandoval, Wendy
Sreedhara, Alavattam
author_sort Hecht, Elizabeth Sara
collection PubMed
description Detection of host cell protein (HCP) impurities is critical to ensuring that recombinant drug products, including monoclonal antibodies (mAbs), are safe. Mechanistic characterization as to how HCPs persist in drug products is important to refining downstream processing. It has been hypothesized that weak lipase–mAb interactions enable HCP lipases to evade drug purification processes. Here, we apply state-of-the-art methods to establish lipase-mAb binding mechanisms. First, the mass spectrometry (MS) approach of fast photochemical oxidation of proteins was used to elucidate putative binding regions. The CH1 domain was identified as a conserved interaction site for IgG1 and IgG4 mAbs against the HCPs phospholipase B-like protein (PLBL2) and lysosomal phospholipase A2 (LPLA2). Rationally designed mutations in the CH1 domain of the IgG4 mAb caused a 3- to 70-fold K(D) reduction against PLBL2 by surface plasmon resonance (SPR). LPLA2-IgG4 mutant complexes, undetected by SPR and studied using native MS collisional dissociation experiments, also showed significant complex disruption, from 16% to 100%. Native MS and ion mobility (IM) determined complex stoichiometries for four lipase-IgG4 complexes and directly interrogated the enrichment of specific lipase glycoforms. Confirmed with time-course and exoglycosidase experiments, deglycosylated lipases prevented binding, and low-molecular-weight glycoforms promoted binding, to mAbs. This work demonstrates the value of integrated biophysical approaches to characterize micromolar affinity complexes. It is the first in-depth structural report of lipase-mAb binding, finding roles for the CH1 domain and lipase glycosylation in mediating binding. The structural insights gained offer new approaches for the bioengineering of cells or mAbs to reduce HCP impurity levels. Abbreviations: CAN, Acetonitrile; AMAC, Ammonium acetate; BFGS, Broyden–Fletcher–Goldfarb–Shanno; CHO, Chinese Hamster Ovary; K(D), Dissociation constant; DTT, Dithiothreitol; ELISA, Enzyme-linked immunosorbent assay; FPOP, Fast photochemical oxidation of proteins; FA, Formic acid; F(ab’), Fragment antibodies; HCP, Host cell protein; IgG, Immunoglobulin; IM, Ion mobility; LOD, Lower limit of detection; LPLA2, Lysosomal phospholipase A2; Man, Mannose; MS, Mass spectrometry; MeOH, Methanol; MST, Microscale thermophoresis; mAbs, Monoclonal antibodies; PPT1, Palmitoyl protein thioesterase; ppm, Parts per million; PLBL2, Phospholipase B-like protein; PLD3, Phospholipase D3; PS-20, Polysorbate-20; SP, Sphingomyelin phosphodiesterase; SPR, Surface plasmon resonance; TFA, Trifluoroacetic acid.
format Online
Article
Text
id pubmed-9621051
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-96210512023-02-07 Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms Hecht, Elizabeth Sara Mehta, Shrenik Wecksler, Aaron T. Aguilar, Ben Swanson, Nathaniel Phung, Wilson Dubey Kelsoe, Ananya Benner, W. Henry Tesar, Devin Kelley, Robert F. Sandoval, Wendy Sreedhara, Alavattam MAbs Report Detection of host cell protein (HCP) impurities is critical to ensuring that recombinant drug products, including monoclonal antibodies (mAbs), are safe. Mechanistic characterization as to how HCPs persist in drug products is important to refining downstream processing. It has been hypothesized that weak lipase–mAb interactions enable HCP lipases to evade drug purification processes. Here, we apply state-of-the-art methods to establish lipase-mAb binding mechanisms. First, the mass spectrometry (MS) approach of fast photochemical oxidation of proteins was used to elucidate putative binding regions. The CH1 domain was identified as a conserved interaction site for IgG1 and IgG4 mAbs against the HCPs phospholipase B-like protein (PLBL2) and lysosomal phospholipase A2 (LPLA2). Rationally designed mutations in the CH1 domain of the IgG4 mAb caused a 3- to 70-fold K(D) reduction against PLBL2 by surface plasmon resonance (SPR). LPLA2-IgG4 mutant complexes, undetected by SPR and studied using native MS collisional dissociation experiments, also showed significant complex disruption, from 16% to 100%. Native MS and ion mobility (IM) determined complex stoichiometries for four lipase-IgG4 complexes and directly interrogated the enrichment of specific lipase glycoforms. Confirmed with time-course and exoglycosidase experiments, deglycosylated lipases prevented binding, and low-molecular-weight glycoforms promoted binding, to mAbs. This work demonstrates the value of integrated biophysical approaches to characterize micromolar affinity complexes. It is the first in-depth structural report of lipase-mAb binding, finding roles for the CH1 domain and lipase glycosylation in mediating binding. The structural insights gained offer new approaches for the bioengineering of cells or mAbs to reduce HCP impurity levels. Abbreviations: CAN, Acetonitrile; AMAC, Ammonium acetate; BFGS, Broyden–Fletcher–Goldfarb–Shanno; CHO, Chinese Hamster Ovary; K(D), Dissociation constant; DTT, Dithiothreitol; ELISA, Enzyme-linked immunosorbent assay; FPOP, Fast photochemical oxidation of proteins; FA, Formic acid; F(ab’), Fragment antibodies; HCP, Host cell protein; IgG, Immunoglobulin; IM, Ion mobility; LOD, Lower limit of detection; LPLA2, Lysosomal phospholipase A2; Man, Mannose; MS, Mass spectrometry; MeOH, Methanol; MST, Microscale thermophoresis; mAbs, Monoclonal antibodies; PPT1, Palmitoyl protein thioesterase; ppm, Parts per million; PLBL2, Phospholipase B-like protein; PLD3, Phospholipase D3; PS-20, Polysorbate-20; SP, Sphingomyelin phosphodiesterase; SPR, Surface plasmon resonance; TFA, Trifluoroacetic acid. Taylor & Francis 2022-10-25 /pmc/articles/PMC9621051/ /pubmed/36284469 http://dx.doi.org/10.1080/19420862.2022.2135183 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Hecht, Elizabeth Sara
Mehta, Shrenik
Wecksler, Aaron T.
Aguilar, Ben
Swanson, Nathaniel
Phung, Wilson
Dubey Kelsoe, Ananya
Benner, W. Henry
Tesar, Devin
Kelley, Robert F.
Sandoval, Wendy
Sreedhara, Alavattam
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
title Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
title_full Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
title_fullStr Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
title_full_unstemmed Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
title_short Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
title_sort insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621051/
https://www.ncbi.nlm.nih.gov/pubmed/36284469
http://dx.doi.org/10.1080/19420862.2022.2135183
work_keys_str_mv AT hechtelizabethsara insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT mehtashrenik insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT wecksleraaront insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT aguilarben insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT swansonnathaniel insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT phungwilson insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT dubeykelsoeananya insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT bennerwhenry insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT tesardevin insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT kelleyrobertf insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT sandovalwendy insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms
AT sreedharaalavattam insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms